Literature DB >> 29352485

Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?

Bahareh Ajami1, Lawrence Steinman1.   

Abstract

Mesh：

Year:  2018        PMID： 29352485     DOI： 10.1111/imcb.12004

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


× No keyword cloud information.
  5 in total

1.  Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation.

Authors:  Tiago Medeiros-Furquim; Sinan Ayoub; Laura J Johnson; Andrea Aprico; Eze Nwoke; Michele D Binder; Trevor J Kilpatrick
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

2.  Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis.

Authors:  Mikkel Carstensen; Tove Christensen; Morten Stilund; Holger J Møller; Eva L Petersen; Thor Petersen
Journal:  Immunol Cell Biol       Date:  2020-05-05       Impact factor: 5.126

3.  Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts.

Authors:  Susan Monkley; Jayendra Kumar Krishnaswamy; Melker Göransson; Maryam Clausen; Johan Meuller; Kristofer Thörn; Ryan Hicks; Stephen Delaney; Louise Stjernborg
Journal:  PLoS One       Date:  2020-12-17       Impact factor: 3.240

4.  Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination.

Authors:  John W Prineas; John D E Parratt
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.685

5.  Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis.

Authors:  David Haschka; Piotr Tymoszuk; Gabriel Bsteh; Verena Petzer; Klaus Berek; Igor Theurl; Thomas Berger; Günter Weiss
Journal:  Front Immunol       Date:  2020-04-29       Impact factor: 8.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.